Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir and Daclatasvir Interaction Study
NCT02082808Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Composite of PK parameters of DTG at Day 5 and Composite of PK parameters of DCV at Day 5. Started Mar 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02082808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082808.